Prostate Health Market

Prostate Health Market Analysis

The prostate health market size stood at USD 39.93 billion in 2025 and is forecast to reach USD 62.88 billion by 2030, rising at a 9.44% CAGR over the period. Growth derives from a swelling cohort of aging males, rapid diffusion of precision diagnostics, and digital-first delivery models that are reshaping patient engagement. Demand accelerates as benign prostatic hyperplasia (BPH) prevalence climbs with age, while falling multigene-test prices encourage earlier, risk-stratified interventions Nature. Direct-to-consumer tele-urology platforms that combine online consultation, laboratory panels, and medicine fulfillment compress waiting times and extend outreach PMC. Meanwhile, clearer U.S. reimbursement pathways for PSMA-PET imaging and radiopharmaceuticals drive pipeline investment, exemplified by Bristol Myers Squibb’s USD 1.3 billion buy-in to RayzeBio’s radioligand assets Fierce Biotech.

Global Prostate Health Market Trends and Insights

Ageing-Male Population Base Swells Addressable Market

Men 65 years and older are the fastest-growing demographic worldwide and are projected to double in developed economies by 2050. BPH prevalence rises from 50% at age 60 to nearly 90% among men in their 90s, while prostate cancer peaks at 102.8 cases per 100,000 in the 65–74 cohort. This demographic wave heightens absolute patient numbers and per-capita utilization, ensuring structural momentum for the prostate health market.

Growing Use of PSA and mpMRI for Early Detection

MRI-first pathways enable 96% of men with negative scans to avoid biopsy without compromising detection of high-grade cancer over 3 years. Combined PSA-mpMRI screening cuts unnecessary biopsies by up to 50% and is quickly embedding into European guideline practice. Such precision approaches strengthen patient confidence and free system resources, boosting adoption across the prostate health market.

Radically Lower Cost of Genomic Testing Enables Risk Stratification

Multigene panel costs have plunged to sub-USD 500, making population-level genetic screening feasible. MyProstateScore 2.0 eliminates 41% of unnecessary biopsies versus 11% under PSA-only criteria, underscoring the clinical and economic upside. Wider payer acceptance should accelerate penetration, adding depth to the prostate health industry’s diagnostics segment.

DTC Tele-Urology Platforms Bundling Meds & Labs

Over 90% of online sexual-health visits are deemed low-risk and safely resolved via teleconsultation. Subscription services combine hormone profiles, PSA kits, and e-prescribing, inducing sticky, recurring revenue and drawing new users into the prostate health market ecosystem.

Adverse-Event Concerns Around Long-Term 5-ARI Usage

Reports linking 5-ARI therapy to erectile dysfunction and mood disorders temper prescription growth. Physicians increasingly shift toward alpha-blocker combinations or device-based therapies such as UroLift, reallocating share within the prostate health market.

Low Reimbursement for Precision Diagnostics Outside US/EU

While Medicare reimburses PSMA-PET scans and gene panels, most emerging markets still rely on PSA alone, stalling adoption of advanced diagnostics. The gap limits global footprint for suppliers yet opens opportunity for lower-cost assays tailored to constrained settings.

Segment Analysis

By Disease Indication: BPH Dominates While Cancer Segment Accelerates

BPH captured 46.56% of the prostate health market size in 2024, propelled by lifelong symptom management and broad therapeutic choice Nature. Pharmaceutical and device makers benefit from steady repeat sales and procedure fees. Conversely, prostate cancer posts the fastest trajectory at a 10.25% CAGR on rising genomic-screen uptake and PSMA-targeted radioligand approvals FDA.

Prostatitis remains smaller but under-served. Emerging microbiota-modifying strategies and localized drug-delivery devices promise fresh options for chronic pelvic pain sufferers Frontiers, signaling latent upside for innovators within the prostate health industry.

By Product Type: Prescription Drugs Lead as Genomics Disrupts

Prescription therapies retained 57.12% of the prostate health market size in 2024 on continued reliance on alpha-blockers, next-generation androgen-receptor inhibitors, and radioligands like Pluvicto^{[1]Source: U.S. Food and Drug Administration, “FDA Expands Pluvicto Indication,” FDA, fda.gov}. Darolutamide’s multiple label extensions underline the advantage of robust clinical pipelines Bayer. Label extensions for Nubeqa and Gemtesa showcase a steady flow of clinical innovation that underpins segment resilience ^{[2]Source: Bayer AG, “Nubeqa Receives Third Prostate Cancer Approval,” Bayer, bayer.com}.

Genomic diagnostics exhibit the highest growth at a 10.78% CAGR as payers weigh real-world savings from avoided biopsies. Minimally invasive devices such as UroLift 2 and Rezūm add high-single-digit growth through procedure volume and geographic reach UroLift.

By Distribution Channel: Hospital Dominance Challenged by Digital Platforms

Hospital pharmacies delivered 51.23% of revenue in 2024 because complex radiopharmaceuticals demand specialist preparation. Tumor boards and same-site imaging also reinforce the channel’s centrality.

Online portals and telemedicine now form the fastest-growing route at an 11.23% CAGR, providing privacy-conscious consumers with convenient refills, home testing, and rapid escalation pathways PMC. Retail chains maintain relevance through over-the-counter products but co-market with digital health apps to secure incremental prescriptions.

Geography Analysis

North America retained 38.51% of the prostate health market share in 2024 and should sustain mid-single-digit growth through 2030. Medicare coverage for PSMA-PET imaging, gene panels, and radioligands supports premium-priced interventions while corporate wellness plans foster routine screening. United States direct-to-consumer models normalize online care seeking, boosting adherence and early detection. Canada’s single-payer system emphasizes cost-effectiveness; its approval of oral relugolix demonstrates willingness to fund drugs that lower hospitalization and injection visits Sumitomo Pharma.

Asia-Pacific is the quickest-growing region at an 11.67% CAGR for 2025–2030. Japan and South Korea lead in mpMRI adoption and guideline-based care, whereas China and India supply high-volume growth but face reimbursement and screening-awareness gaps. Governments roll out public-private campaigns pairing hospital-based “check-up days” with tele-follow-ups to bridge access issues, drawing multinationals and local startups into the prostate health market.

Europe follows an evidence-centric path that tempers uptake speed but ensures durability. Health-technology-assessment agencies tie reimbursement to real-world cost-utility, favoring scans and therapies with demonstrated survival or quality-of-life benefit. Germany and France increasingly rely on multiparametric MRI for biopsy triage, while the United Kingdom’s National Health Service pilots risk-adapted screening.

The Middle East and Africa remain nascent yet promising. Rising life expectancy, private-sector hospital build-outs, and government screening drives create incremental demand. Constraints include low urologist density and fragmented payer systems, but PSMA-PET installations in Gulf Cooperation Council states illustrate gradual capability upgrades Nature.

Competitive Landscape

The prostate health market marries established pharmaceutical incumbents, device innovators, and digital disruptors. Bayer, Pfizer, and Merck harness multi-indication development of androgen-receptor inhibitors; darolutamide’s third U.S. approval showcases this strategy Bayer. Bristol Myers Squibb’s acquisition of RayzeBio grants immediate entry into late-stage radiopharmaceuticals and underlines investor appetite for targeted modalities

Device firms such as Boston Scientific and Teleflex expand portfolios with minimally invasive BPH tools that prioritize sexual-function preservation. The UroLift 2 platform, now cleared for all prostate anatomies, and Rezūm steam therapy deliver rapid symptom relief and shorter recovery windows, enabling outpatient procedural expansion UroLift.

Digital-first platforms tackle cultural reluctance toward clinic visits. Subscription models provide on-demand testing, teleconsultation, and doorstep dispensing, capturing users who might otherwise remain untreated. Incumbents integrate virtual touchpoints or partner with e-pharmacies to avoid leakage. Competition increasingly hinges on real-world outcome evidence and payer alignment, with market access teams weighing cost-per-QALY metrics.